A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder 
Introduction
Major depressive disorder (MDD) is a chronic, disabling disorder characterized by a wide range of emotional and physical symptoms that may be linked via shared serotonergic and noradrenergic pathways (Greden, 2003) . Although psychological symptoms are central features of MDD, an international study has reported that approximately 69% of patients may present with only physical symptoms, such as backaches, fatigue, gastrointestinal disturbances, and pain in the joints and limbs (Simon et al., 1999; Trivedi, 2004) .
Treatment of MDD is aimed at improving both emotional and physical symptoms, and eventually at achieving remission, the ultimate goal of antidepressant therapy (Kupfer, 1991; Stahl, 1999; Nemeroff et al., 2002; Greden, 2003 ). An estimated 50% of patients, however, with MDD discontinue antidepressant treatment owing to side effects or insufficient response, and more than 50% fail to achieve remission, even if they initially respond (Nemeroff et al., 2002; Nelson et al., 2004) . Recent findings from the National Institute of Mental Health's Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that approximately 70% of patients with MDD do not achieve remission following adequate treatment with a selective serotonin reuptake inhibitor (Trivedi et al., 2006) . Thus, there is a need to develop new therapeutic options for the treatment of MDD.
Currently, a novel dual-acting agent, desvenlafaxine succinate (desvenlafaxine), is under investigation for the treatment of MDD. Desvenlafaxine is the only major active metabolite of the antidepressant venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), and desvenlafaxine extended-release tablets are in development for MDD. Similar to venlafaxine, desvenlafaxine inhibits the neuronal reuptake of both serotonin and norepinephrine and, to a lesser degree, the reuptake of dopamine. It does not have any monoamine oxidase inhibitory activity, and shows virtually no affinity for rat brain muscarinic, cholinergic, H 1 -histaminergic, or a-1-adrenergic receptors. Desvenlafaxine has been examined in a series of preclinical in-vivo and in-vitro tests and has been found to be active in multiple models used to predict antidepressant activity.
The pharmacokinetic profile of desvenlafaxine has been evaluated in phase 1 clinical trials (data on file, Wyeth Research). After oral administration, desvenlafaxine is well absorbed (80% bioavailability), and the mean terminal-phase elimination half-life (t 1/2 ) of desvenlafaxine from desvenlafaxine extended release is approximately 9-10 h. Therefore, steady-state concentrations of desvenlafaxine can be attained in 3-4 days after oncedaily treatment. Desvenlafaxine provides a stable concentration profile over the dosing interval, while offering ease of use in a once-daily dose administration. Desvenlafaxine may have a low potential for drug-drug interactions because elimination occurs primarily by phase II metabolism to form a glucuronide conjugate metabolite, by renal excretion of unchanged desvenlafaxine. In addition, desvenlafaxine is associated with minimal inhibition of CYP450 enzymes (Shilling et al., 2005, Conference Proceeding) .
The primary objective of this phase III pivotal trial was to compare the antidepressant efficacy and safety of oncedaily doses of desvenlafaxine 200 mg and desvenlafaxine 400 mg with placebo for the treatment of MDD. Dose selection for this trial was informed by tolerability results from phase I pharmokinetic studies. The secondary objectives were to compare clinical global evaluation of improvement, functionality, general well-being, pain, and remission in patients treated with desvenlafaxine or placebo.
Methods
The study was conducted at multiple centers in Europe (n = 30) and South Africa (n = 5). The protocol received independent ethics committee approval before the study began. The protocol amendments were approved when the study was in progress and before the data were unblinded. The study was consistent with Good Clinical Practice and the applicable regulatory requirements in each participating country. All participants provided written informed consent before enrollment.
Participants

Inclusion criteria
Participants were healthy outpatients aged 18-75 years with a primary diagnosis of MDD, according to the Diagnostic and statistical manual for mental disorders, fourth edition criteria, and in a single or recurrent episode without psychotic features. Each participant had depressive symptoms for at least 30 days before screening. The following minimum scores were required at both screening and baseline: a total score Z 20 on the 17-item Hamilton Rating Scale for Depression (HAM-D 17 ); a score Z 2 on item 1 (depressed mood) of the HAM-D 17 ; and a score Z 4 (moderately ill) on the Clinical Global Impressions-Severity (CGI-S) scale. All sexually active women in the study were on medically acceptable contraception, including oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception.
Exclusion criteria
Participants were excluded from the trial if they had received prior treatment with desvenlafaxine, had received treatment with venlafaxine immediate-release or extended-release within 90 days of baseline, or had known hypersensitivity to venlafaxine (immediate or extended-release). Participants were also excluded if they met any of the following criteria: at significant risk of suicide on the basis of the clinical judgment; pregnant, breast-feeding, or planning to become pregnant during the study; current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, clinically important personality disorder, or lifetime diagnosis of bipolar or psychotic disorder as assessed by the modified Mini-International Neuropsychiatric Interview; current (within 12 months before baseline) generalized anxiety disorder, panic disorder, or social anxiety disorder that the investigator considered primary based on a modified Mini-International Neuropsychiatric Interview assessment; Covi Anxiety Scale total score greater than the Raskin Depression Scale total score at screening or baseline; Covi Anxiety Scale score > 3 on any single item or a total score > 9 at screening or baseline; depression because of a general medical condition or neurologic disorder; history of a seizure disorder; clinically important medical disease; gastrointestinal disease or surgery known to interfere with the absorption or excretion of drugs; neoplastic disorder (except basal or squamous cell carcinoma of the skin) within 2 years; presence of raised intraocular pressure or history of narrow angle glaucoma; major acute illness within 90 days before screening; myocardial infarction within 180 days before screening; clinically important abnormalities on screening physical examinations, electrocardiograph (ECG) or laboratory analyses; or use of prohibited treatments.
Study design
This was a phase III, randomized, double-blind, parallelgroup, placebo-controlled multicenter trial. After a screening period of 6-14 days, eligible participants were randomly assigned to 8 weeks of treatment with desvenlafaxine 200 mg/day, desvenlafaxine 400 mg/day, or placebo, followed by a taper period of 2 additional weeks. A follow-up visit was scheduled for approximately 7 days after the end of the taper period. Participants who completed the 8-week double-blind trial had the option to continue desvenlafaxine treatment in a separate long-term, open-label extension study. Those who continued into the extension study did not have their doses tapered nor did they have a follow-up evaluation.
Treatment
At baseline, participants were randomly assigned to 1 of 2 fixed doses (200 or 400 mg/day) of desvenlafaxine or placebo. Participants in the 200-mg dose group received their assigned maintenance dose on study day 1. Participants in the 400-mg group had their dose titrated during week 1. On study days 1 through 7, they received 200 mg/day of desvenlafaxine; starting on day 8, participants received their assigned maintenance dose of 400 mg/day of desvenlafaxine. For both groups, the assigned maintenance dose of desvenlafaxine was maintained until day 56 or early withdrawal.
Participants who discontinued early or who did not continue in the long-term open-label study had their doses tapered over a 2-week period. During the taper period, participants in the desvenlafaxine 200-mg/day group had their dose reduced to 100 mg/day for taper days 1 through 7; for taper days 8 through 14, the dose was discontinued completely. For participants in the desvenlafaxine 400-mg/day group, the dose was reduced to 200 mg/day for taper days 1 through 7; for taper days 8 through 14, the dose was reduced to 100 mg/day.
During the study, the following concomitant therapy was permitted: nonpsychopharmacologic drugs with psychotropic effects if the participant had been receiving a stable dose for at least 90 days before study day 1; common cold preparations; zaleplon or zolpidem up to 10 mg at bedtime, three times per week for approximately the first 14 days of treatment; supportive nonbehavioral psychotherapy provided there had been no change in intensity or frequency within the last 180 days and no change occurred during the study; cimetidine and clonidine; beta-adrenergic receptor blockers for cardiovascular disease if the participant had been on a stable dose for at least 30 days before study day 1.
Efficacy and safety assessments
The primary measure of efficacy was the change from baseline to final on-therapy (FOT) evaluation in mean total scores of the HAM-D 17 , which was administered at each visit. The secondary measures of efficacy included the CGI-Improvement (CGI-I) score, which ranged from 1 (very much improved) to 7 (very much worse) and which was also administered at each visit after randomization; the Montgomery-Åsberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) total scores, CGI-S scores, remission (defined as a HAM-D 17 score r 7), response (defined as a Z 50% reduction in scores on the HAM-D 17 ), and Visual Analog Scale-Pain Intensity (VAS-PI) overall and subscale scores. The CGI-S was administered at each visit, while the MADRS and VAS-PI were administered at baseline and on study days 14, 28, and 56.
Safety evaluations performed at each visit included monitoring of adverse events (AEs), discontinuations owing to AEs; assessment of blood pressure, pulse, and weight; recording of concomitant treatments; and review of treatment compliance. A physical examination and laboratory determinations (hematology, blood chemistry, and urinalysis) were performed at screening and day 56. A single 12-lead ECG recording was made at screening, and three separate 12-lead ECG recordings were made at baseline and day 56 (or at early withdrawal).
Statistical analysis
Sample size estimates were based on the HAM-D 17 total score, which was the primary efficacy measure. On the basis of experience with venlafaxine extended-release, a standard deviation of 8 units was selected for use in the calculations. A sample size of 111 participants per group was determined to be sufficient to declare a statistically significant mean difference between the desvenlafaxine and placebo treatment groups of 3.5 units at the 5% level with a power of approximately 90%. To compensate for participants who failed to qualify for the intent-to-treat (ITT) analysis (5% of all participants), 120 participants were randomly assigned to each group.
All efficacy analyses were based on the ITT population, which included all participants who were randomized to treatment, had a baseline primary efficacy evaluation, took at least 1 dose of study medication, and had at least 1 primary efficacy evaluation after the first dose of doubleblind test medication. For all primary and secondary efficacy measures, the FOT evaluation was the primary end point. Efficacy analyses were performed at each evaluation period and the last-observation-carried-forward (LOCF) method was used to account for results of early terminators. Primary and secondary efficacy end points were reported for the final evaluation, using LOCF.
Baseline characteristics of treatment groups were compared using analysis of variance and the Fisher exact test. Changes from baseline on all efficacy measures, except CGI-I scores, were evaluated using analysis of covariance with treatment and site as factors and baseline scores as the covariate. CGI-I scores were analyzed using analysis of variance with treatment and site as factors. The Fisher exact test was used to analyze rates of response and remission. Statistical significance was declared at the 0.05 level.
Additional analyses to correct for patterns of missing data were performed with the HAM-D 17 . The two additional pre-specified efficacy analyses were observed: case and mixed effect model. The mixed effect model analyzes all data, taking into account the correlation between observations.
Safety analyses were based on the safety population, which included all participants who were randomized to treatment and took at least 1 dose of double-blind test medication.
Results
Participants
A total of 375 participants were randomly assigned to treatment (124 to desvenlafaxine 200 mg/day, 125 to desvenlafaxine 400 mg/day, and 126 to placebo). Of these, 373 participants were included in the safety analyses (two participants had no study medication use). The ITT population included 369 participants who were evaluated for efficacy; six participants were excluded from the ITT population because they did not take test medication, had no postbaseline data, or did not have a primary efficacy evaluation (HAM-D 17 ) on therapy (Fig. 1) . A total of 93 (25%) participants discontinued the study, 33 (27%) participants treated with desvenlafaxine 200 mg/day, 33 (26%) treated with desvenlafaxine 400 mg/day, and 27 (22%) treated with placebo. The most common reason for discontinuing treatment was AEs with desvenlafaxine (20 and 21% in the desvenlafaxine 200 and 400-mg/day groups, respectively) and unsatisfactory clinical response in the placebo group (12%). No significant differences were found among treatment groups in baseline demographic and clinical characteristics (Table 1) .
Treatment
During the double-blind period between days 8 (after the initial titration period) and 56, the mean daily doses of desvenlafaxine in the safety population ranged from 198.3 to 199.4 mg in the 200-mg/day group and from 388.7 to 399.4 mg in the 400-mg/day group. No participant had a mean daily dose greater than 400 mg.
The use of concomitant medications and the types of medications given during the double-blind period were similar between treatment groups. Concomitant therapy was used by 85 (68%) participants in the placebo group, 83 (67%) in the desvenlafaxine 200-mg/day group, and 83 (66%) in the desvenlafaxine 400-mg/day group. The most frequently used concomitant medications were analgesics and antipyretics, nonsteroidal anti-inflammatory/antirheumatic products, and hormonal contraceptives.
Efficacy evaluation Primary efficacy measure
At the FOTevaluation, adjusted mean change ( ± SE) from baseline in HAM-D 17 total scores was significantly greater for desvenlafaxine 200 mg/day ( -12.6 ± 0.75; P = 0.002) and desvenlafaxine 400 mg/day ( -12.1 ± 0.74; P = 0.008), compared with placebo ( -9.3 ± 0.74) (Fig. 2 ). Significant differences in HAM-D 17 total scores (LOCF) vs. placebo were observed starting at week 4 for both desvenlafaxine 200 mg/day (P r 0.004) and desvenlafaxine 400 mg/day (P r 0.049), and were sustained until the end of the study.
The results of the additional prespecified efficacy analyses were similar to the FOT evaluation. Both doses of desvenlafaxine (200 and 400 mg/day) were significantly different from placebo for the primary efficacy measure (HAM-D 17 total score) for the observed case at week 8 and the mixed effect model analyses (P < 0.001 for both doses in each analysis). In the observed case analysis, significant separation from placebo started at week 2 for the desvenlafaxine 200-mg/day group and at week 3 for the desvenlafaxine 400-mg/day group.
Secondary efficacy measures
At the FOT evaluation, significantly lower mean ( ± SE) CGI-I scores were noted for both desvenlafaxine 200 and 400 mg/day vs. placebo (2.2 ± 0.12, 2.3 ± 0.12, and 2.7 ± 0.12, respectively; P < 0.05 vs. placebo). Significant differences in mean CGI-I scores (LOCF) vs. placebo were observed for desvenlafaxine 200 mg/day starting at week 3 (P = 0.013) and for desvenlafaxine 400 mg/day starting at week 6 (P = 0.02), with a trend toward significance at week 4 (P = 0.064); significant differences for both groups were sustained until the end of the study. Rates of HAM-D response and remission at the FOT evaluation and results from categorical data analyses are shown in Fig. 3 . Rates of Baseline CGI-S, mean (SD) 4.9 (0.7) 4.9 (0.7) 4.9 (0.7)
CGI-S, Clinical Global Impressions-Severity scale; DVS, desvenlafaxine succinate; HAM-D 17 , 17-item Hamilton Rating Scale for Depression; ITT, intentto-treat. response were significantly higher with desvenlafaxine 200 and 400 mg/day than with placebo (P < 0.001 and P = 0.005, respectively). Response rates were 60, 56, and 38% for desvenlafaxine 200 mg/day, desvenlafaxine 400 mg/day, and placebo, respectively. Significantly more participants treated with desvenlafaxine 200 mg/day achieved remission at the FOT evaluation, compared with placebo (37 vs. 23%, respectively; P = 0.017). Although not statistically significant, remission rates on the HAM-D 17 were numerically higher for desvenlafaxine 400 mg/day than for placebo (34 vs. 23%, respectively; P = 0.066).
A logistic regression analysis of HAM-D 17 response rates produced similar results. At the FOT evaluation, the adjusted odds ratio for response, relative to placebo, was 2.410 [95% confidence interval (CI) = (1.43, 4.07)] in the desvenlafaxine 200-mg/day group (P = 0.001) and 2.155 [95% CI = (1.28, 3.62)] in the desvenlafaxine 400-mg/day group (P = 0.004). Thus, the odds of achieving a response when treated with desvenlafaxine 200 and 400 mg/day were significantly greater (2.4 and 2.1 times, respectively), than the odds of achieving a response when treated with placebo.
Changes from baseline to FOT evaluation were significantly different for desvenlafaxine 200 and 400 mg/day vs. placebo for MADRS total score (P = 0.001 and P = 0.005, respectively) and CGI-S score (P = 0.001 and P = 0.013, respectively). At the FOT evaluation, the decrease from baseline in the adjusted mean overall pain score was significantly greater in the desvenlafaxine 200-mg/day group compared with the placebo group (P = 0.002). An observed trend toward significance vs. placebo for the desvenlafaxine 400-mg/day group (P = 0.053) existed. In addition to significant differences in the VAS-PI overall pain score, the desvenlafaxine 200-mg/day group was significantly better than placebo on the VAS-PI subscale scores for chest pain and pain in the arms, legs, or joints. Treatment with desvenlafaxine 400 mg/day was significantly better than placebo on the VAS-PI subscale scores for back, chest, and arms, legs, or joint pain (Table 2) .
Safety evaluation Adverse events
Treatment-emergent adverse events (TEAEs) were reported by 88 (70%) placebo participants, 104 (85%) desvenlafaxine 200-mg/day participants, and 113 (90%) desvenlafaxine 400-mg/day participants. The most common TEAEs (i.e. those reported by at least 5% of participants in either desvenlafaxine treatment group and at a rate at least twice that of placebo) are presented in Table 3 . Most TEAEs were generally mild or moderate in severity. Nausea occurred at the highest frequency (46 and 50% in desvenlafaxine 200 and 400-mg/day groups, respectively, compared with 11% in the placebo group). Less than 5% of women experienced a decrease in libido and approximately 10% of men experienced abnormal ejaculation with either dose of desvenlafaxine treatment. Impotence was reported by approximately 5% of men in both the placebo and desvenlafaxine 200-mg/day groups, and by 15% of men in the desvenlafaxine 400-mg/day group. The incidence over time of the most common TEAEs (nausea, dry mouth, sweating, dizziness, asthenia, and constipation) revealed that frequencies were highest during the first week of treatment, and decreased rapidly so that from week 3 onward no major differences could be observed between desvenlafaxine and placebo treatment groups (data not shown).
The discontinuation of participants was highest during the first week of treatment for the desvenlafaxine groups, with AEs the most common reason for discontinuation (Fig. 1) . In the desvenlafaxine 200-mg/day group, of the 20 participants who discontinued during the first week, 18 did so due to an AE; in the desvenlafaxine 400-mg/day group, all participants (n = 14) who discontinued during the first week did so due to an AE. No marked differences in discontinuation rates were observed between desvenlafaxine and placebo treatment groups after the first week of treatment. Among participants who cited AEs as a primary or secondary reason for discontinuing double-blind treatment, nausea was the most common reason for discontinuation among desvenlafaxine-treated participants: 9 (7%) in the desvenlafaxine 200-mg/day group and 14 (11%) in the desvenlafaxine 400-mg/day group. Nausea was reported most frequently during the first week of treatment, with an incidence of 42, 46, and 7% for participants treated with desvenlafaxine 200, 400 mg/day, and placebo, respectively. The incidence of nausea became less frequent over time. During week 2, the incidence for participants treated with desvenlafaxine 200, 400 mg/day, and placebo was 5, 5, and 2%, respectively. By week 3 the incidence of nausea for either dose of desvenlafaxine was not different from placebo. Similarly, the majority of discontinuations owing to nausea occurred during the first week of treatment; the remainder discontinued during weeks 2 and 3, and thereafter no participants in any treatment group discontinued owing to nausea.
Four participants had TEAEs of clinical interest. One placebo participant experienced leucopenia, which did not result in treatment discontinuation and was assessed by the investigators as probably not related to treatment. Another placebo participant experienced suicidal ideation/anxiety after 12 days on therapy, which lead to treatment discontinuation and was assessed as possibly related to treatment. One participant in the desvenlafaxine 200-mg/ day group experienced depression/suicidal ideation after 25 days on therapy, which was assessed as probably not related to treatment and did not result in discontinuation. Finally, one participant in the desvenlafaxine 400-mg/day group had tachycardia, which was assessed as possibly related to treatment but did not result in discontinuation.
No serious AEs or deaths associated with desvenlafaxine during or immediately after the study were seen.
Laboratory evaluations
Both desvenlafaxine 200 mg/day and desvenlafaxine 400 mg/day were associated with significant changes from baseline in mean bilirubin (decreases) and alkaline (8) 13 (10) Vertigo 3 (2) 13 (11) 9 (7) Sweating 9 (7) 34 (28) 36 ( phosphatase (increases) values. In the desvenlafaxine 400-mg/day group, significant increases from baseline were also observed for mean ALT/SGPT, AST/SGOT, GGT, and fasting HDL cholesterol values. None of these parameters showed significant changes in the desvenlafaxine 200-mg/day group (Table 4A ). The mean decreases observed for bilirubin had no clinical impact. Similarly, the mean increases in liver enzymes were not accompanied by clinical symptoms, even when these increases met criteria for potential clinical importance, and were reversed when participants discontinued desvenlafaxine treatment. Three participants in the desvenlafaxine treatment groups had clinically important changes, as determined by the study medical monitor on the basis of clinical judgment, in laboratory test results (one participant in the desvenlafaxine 200-mg/day group experienced increased AST and ALT; a second participant in the desvenlafaxine 200-mg/day group experienced increased cholesterol; and one participant in the desvenlafaxine 400-mg/day group experienced increased AST, cholesterol, and triglycerides). Comparison on the basis of the adjusted mean changes from baseline using ANCOVA with baseline as the covariate. Significant differences between groups are shown only if the overall comparison was significant. ANCOVA, analysis of covariance; DVS, desvenlafaxine succinate. Comparison on the basis of adjusted mean changes from baseline using ANCOVA with baseline as the covariate. Significant differences between groups are shown only if the overall comparison was significant. ANCOVA, analysis of covariance; BP, blood pressure; bpm, beats per minute; DVS, desvenlafaxine succinate. Comparison on the basis of adjusted mean changes from baseline using ANCOVA with baseline as the covariate. Significant differences between groups are shown only if the overall comparison was significant. bpm, beats per minute; DVS, desvenlafaxine succinate.
Vital signs
Desvenlafaxine 400 mg/day was associated with small but significant increases from baseline in mean pulse rate and diastolic blood pressure; significant decreases from baseline in mean body weight were observed for participants in the desvenlafaxine 200 and 400-mg/day groups. The increases observed with desvenlafaxine 400 mg/day were significantly greater than placebo for pulse rate, diastolic blood pressure, and weight, whereas significant differences vs. placebo were observed with desvenlafaxine 200 mg/day for pulse rate, systolic blood pressure, diastolic blood pressure, and weight (Table 4B ). One participant in the desvenlafaxine 400-mg/day group had a clinically important increase in standing and supine diastolic blood pressure.
Electrocardiogram
Several small but significant mean changes from baseline in ECG parameters were observed with desvenlafaxine treatment; however, most of the changes were attributable to the increases observed in mean heart rate. The small but significant increases from baseline in mean QTcB interval values in the desvenlafaxine treatment groups is consistent with the overcorrection of QTcB with increased heart rate ( Table 4C) .
Discussion
The majority of participants treated with fixed desvenlafaxine doses in this study experienced significant improvement in a broad range of emotional and functional depressive symptoms. Desvenlafaxine 200 and 400-mg/ day treatments showed significant differences from placebo on the primary efficacy measure, the mean change from baseline on HAM-D 17 total score. Similarly, desvenlafaxine 200 and 400 mg/day were also significantly better than placebo on the CGI-I score, as well as on several other secondary efficacy measures, including the CGI-S score. Both desvenlafaxine treatment groups also showed an improvement on MADRS total score significantly superior to placebo.
By exploring categorical outcomes, this study showed that response rates at the end of the study on the HAM-D 17 were robust (60 and 56%, respectively, for desvenlafaxine 200 and 400 mg/day), and markedly separate from placebo. Therapy with desvenlafaxine also showed efficacy for treating depression to remission; the rate of remission observed in this trial is consistent with the 35 to 45% commonly reported in other short-term studies of SNRIs (Thase et al., 2001; Stahl, 2002) . Achieving a state of absence of symptoms (remission) was proposed to be a standard for treatment of depression, as it might decrease risk for relapse or recurrence of depressive episodes (Nierenberg and Wright, 1999) .
Although participants' selection was not on the basis of the intensity of painful physical symptoms, an exploratory analysis was conducted on the effect of desvenlafaxine on these symptoms. Treatment with desvenlafaxine 200 and 400 mg/day was associated with significant improvements in painful symptoms commonly associated with MDD, supporting other data on SNRIs (Bradley et al., 2003; Brannan et al., 2005) . The finding that desvenlafaxine therapy alleviated painful physical symptoms associated with depression is clinically relevant in light of a literature review of 14 studies that showed pain is commonly reported by a mean of 65% of depressed patients and that moderate to severe pain in depression is associated with poor treatment response and a lower quality of life (Bair et al., 2003) .
Desvenlafaxine was generally safe and well tolerated in this study. In most cases, TEAEs were mild to moderate in severity. Although almost half of the participants treated with desvenlafaxine experienced transient nausea, symptoms resolved by day 7 of treatment for the majority of participants. Likewise, most of the discontinuations owing to nausea occurred during days 1-7 of treatment and diminished over time. Nausea was not unexpected in this trial because it is frequently associated with SNRIs and has been commonly cited as a primary reason for treatment discontinuation in trials of SNRIs (Danjou and Hackett, 1995; Rudolph and Derivan, 1996; Westanmo et al., 2005) . The pattern of AEs reported with desvenlafaxine is thus consistent with this class of antidepressant, and desvenlafaxine was also associated with few clinically important changes in laboratory tests, vital signs measurements, or ECG assessments. Importantly, the titration schedule used in this study may have affected tolerability; there was no dose titration for the desvenlafaxine 200-mg/day treatment group, and the desvenlafaxine 400-mg/day treatment group was initiated on a dose of 200 mg/day. A direct initiation of a desvenlafaxine dosage of 200 mg/day might be related to the discontinuation rates that were highest during the first week of treatment for both desvenlafaxine groups, with a majority of participants discontinuing owing to AEs. Starting participants on a lower dose of desvenlafaxine may improve tolerability and reduce the incidence of nausea and other frequently reported AEs, both overall and at treatment onset. A different titration schedule was investigated in another clinical study with doses ranging from 100 to 400 mg daily (DeMartinis et al., 2006) . With the alternate dosing scheme, a lower TEAE profile was observed with lower doses of desvenlafaxine.
Strengths of this study include the randomized, placebocontrolled trial design and the broad range of efficacy and safety measures employed. The generalizability of the results is limited by the short duration (8 weeks) of treatment and the criteria for selection of patient population. Another limit was related to the study design that imposed fixed dose of treatment, and therefore did not offer the possibility for the practitioner to optimize treatment outcome by adjusting the desvenlafaxine daily dose. Additional studies are needed, including those with longer treatment durations and more diverse patient populations.
In conclusion, given the recent STAR*D findings that approximately one half of patients with MDD do not respond after adequate first-line treatment with a selective serotonin reuptake inhibitor (Trivedi et al., 2006) , the efficacy results of this study indicate that there is now a new, viable option for the treatment of MDD. This study suggests that single daily doses of desvenlafaxine 200 mg and desvenlafaxine 400 mg were generally well tolerated for the treatment of MDD and showed significantly greater improvements than placebo on measures of efficacy, including response, global clinical improvement, functional status, and pain. These results also suggest that desvenlafaxine might be effective in treating a range of symptoms associated with MDD. Future studies are warranted to further evaluate the dose-response effects and clinical impact of different doses of desvenlafaxine for the treatment of MDD.
